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VI. Abstract 
 
Title 
Biophysical Analysis of Anti-Inflammatory Viral CC Chemokine Binding Protein vCCI 
 
Laura Janelle Showalter 
Master of Science 
University of California, Merced 
2018 
Supervisor: Professor Patricia LiWang 
 
 
Viruses have evolved mechanisms to subvert the immune system by interfering 
with chemokine signaling. The two mechanisms of evasion discussed in this thesis are 
proteins which bind chemokines to prevent them binding their receptors (as vCCI does) 
and chemokine analogs (such as vMIP-II) that competitively inhibit chemokines. 
Molecular dynamics simulations suggested that Y80 in vCCI is important for propping 
open the acidic loop, which keeps the binding site open. We investigated this hypothesis 
using ITC, NMR, and CD. For vCCI WT and vCCI Y80A, results included: a higher KD for 
the mutant (2.99 x 10-8 M) when binding vMIP-II compared to vCCI WT (≤1.00 x 10-10 M), 
key residues involved in binding shifted in the unbound mutant NMR HSQC spectrum, 
and the mutant had lower stability demonstrated by a 6.1°C reduction in Tm. The Y80A 
mutation lowers chemokine affinity, which may indeed be due to collapse of the 
substrate-binding loop. 
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Chapter 1 
 
Introduction 
 
1.1 Chemokines and Inflammation 
1.1.1 Inflammation 
Inflammation occurs when there is an immune response in an area of the body. 
This commonly happens with injury or infection. The immune response is life-saving. It 
keeps foreign invaders out of the body and promotes the healing process. An important 
player in directing white blood cells to the area of interest are chemotactic cytokines, 
called chemokines. They are small proteins, about 8-10 kDa in size, which are secreted 
and mediate chemotaxis. The chemokines then create a chemoattractant gradient, with 
the greatest concentration of chemokines near the affected site and lessening with 
diffusion away from the site. Glycosaminoglycans (GAGs) promote their oligomerization 
and allow reversible immobilization, helping to form the gradient.1 Circulating leukocytes 
have cell surface G-protein coupled chemokine receptors which will respond to 
extracellular chemokines and follow the chemokine gradient to the site of injury or 
infection.  
While inflammation is an important part of the immune response, it also is 
involved in several pathologies. For instance, asthma is characterized by chronic 
swelling of the airway. Understanding inflammation and studying ways to perturb the 
immune response is key for the development of drugs for diseases that involve 
inflammation. Research in inflammation has wide applications in the medical field. 
 
1.1.2 Chemokines and Chemokine Receptors 
Humans have about 50 chemokines and 20 chemokine receptors.2 Both the 
chemokines and the receptors that bind them are named in part by the conserved 
cysteine location patterns in the chemokines. There are 4 subclasses of chemokines: C, 
CC, CXC, and CX3C, which indicates the proximity of cysteines to each other near the 
N-terminus of the chemokine (with X being an amino acid other than cysteine). An 
example of a chemokine name is CCL5: within the CC subclass, ligand 5. The receptor 
names have a similar naming convention, except they have R for receptor, instead of L 
for ligand (e.g. CCR5). The receptors are separated into these subclasses based on 
what subclass of chemokine they bind. Generally, receptors only bind one subclass of 
chemokines, but they can usually promiscuously bind several chemokines within that 
subclass.1 
Chemokines have a characteristic Greek key fold with two disulfide bonds that 
include the cysteines near the N-terminus bonding to cysteines that are near the middle 
and end of the sequence. They have antiparallel β-sheets connected by loops, with an 
α-helix near the C-terminus.1 The N-terminus is important for interaction with chemokine 
receptors, resulting in different levels of signaling and sequestration of the receptor.3 
Chemokine receptors are G-protein-coupled receptors (GPCRs). GPCRs have 
seven transmembrane helices, with their N-terminus on the extracellular side of the 
membrane and their C-terminus on the cytoplasmic side. The N-terminus can become 
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post-translationally modified. Post-translationally sulfating tyrosine residues at the N-
terminus of chemokine receptors to make them negatively charged has been shown to 
be important for tighter binding with positively charged chemokines.4 Binding events can 
cause a structural change which allows G proteins, which are associated with the 
receptor on the cytoplasmic side, to become activated (replacement of GDP with GTP) 
and cause downstream signaling. The C-terminus is involved in receptor desensitization 
through becoming phosphorylated by βARK, subsequently associating with β-arrestin, 
and the receptor being endocytosed where it is dephosphorylated before returning to the 
cell surface.1 There are additional ways the signal can be stopped besides 
desensitization. An effective signaling process must be able to stop after a stimulus has 
stopped and respond again when the stimulus reemerges.  
 
1.1.3 Viral Subversion of the Chemokine Signaling Pathway 
Several viruses have evolved means to subvert the immune system and allow for 
successful infection and reproduction using the host machinery. Some viruses dedicate 
half of their genome to evading the immune system.5 Focusing on the chemokine 
signaling pathway specifically, it can be disrupted by stopping chemokines from binding 
to their receptors. This can be done in several ways, such as inhibition of chemokine 
production or maturation in the first place, blocking of the chemokine receptors’ binding 
sites through chemokine analogs, and binding chemokines directly via chemokine 
binding proteins or receptor analogs so they cannot go on to bind their receptors, among 
other ways.6 In my work, I have focused on the protein vCCI, encoded by poxviruses, 
which promiscuously and tightly binds the CC subclass of chemokines. I have also 
worked with vMIP-II, a protein encoded by herpesvirus that acts as a chemokine analog 
that binds chemokine receptors but generally does not cause downstream signaling. It 
competitively inhibits chemokine binding.  
 
1.2 vMIP-II 
1.2.1 Function 
vMIP-II stands for viral macrophage inflammatory protein type II. It is a human 
herpesvirus-8 (HHV-8) encoded protein that is a chemokine analog. It binds and 
occludes chemokine receptors, generally without causing downstream signaling. Thus, it 
is chemokine receptor antagonist that operates as a competitive inhibitor. vMIP-II also 
binds GAGs more tightly than natural chemokines, further reducing inflammation by 
reducing the formation of a chemoattractant gradient.7 Besides the anti-inflammatory 
properties of vMIP-II, it is also an HIV inhibitor due to its ability to bind both the co-
receptors HIV exploits (CCR5 and CXCR4) to gain entrance into cells.8 
 
1.2.2 Protein Characteristics 
vMIP-II is 72 residues and about 8 kDa in size. It consists of a flexible N-
terminus, followed by the N-loop, three β-sheets connected by loops, and an α-helix 
near its C-terminus.8 It has a very similar structure to CC chemokines, with two disulfides 
located as expected for CC chemokines. 
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vMIP-II protein sequence used in experiments:  
GLGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQLCSKPGVIFLTKRGRQVCADKSK
DWVKKLMQQLPVTAR 
Table 1.1. vMIP-II Protein Characteristics 
Characteristic Value 
Amino Acids 72 
Molecular Weight 8186 Da 
Theoretical pI 10.05 
Extinction Coefficient 19730 M-1cm-1 
 
Figure 1.1. vMIP-II structure (PDB: 1VMP). Figure was made using UCSF Chimera.9 
 
1.3 vCCI 
1.3.1 Function 
vCCI stands for viral CC chemokine inhibitor. As the name alludes, it 
promiscuously binds CC type chemokines, making them unable to bind to their 
endogenous receptors.10–12 It is encoded by poxviruses. It binds many CC chemokines 
more tightly than their receptors do. Burns, et al. showed vCCI binding to over 80 viral, 
human, and murine CC chemokines, 26 of which were high-affinity binders (greater than 
75% inhibition of MIP-1β binding to vCCI).12 
 
 
1.3.2 Protein Characteristics 
Historically, vCCI was called p35 for a protein having a mass of 35 kDa observed 
on SDS-PAGE.11 The actual mass of the rabbitpox protein is about 26 kDa, but it runs a 
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little heavy (close to 35 kDa) on SDS-PAGE. While it binds chemokines tightly, its 
structure is not similar to chemokine receptors.13 It is largely composed of β-sheets, with 
only one α-helix in the entire protein (which is more than 240 amino acids). It has 4 
disulfide bonds and is very stable once folded. 
vCCI ‘wild-type’ protein sequence (rabbitpox strain) used in experiments: 
AMAASLQQSSSSSSSCTEEENKHHMGIDVIIKVTKQDQTPTNDKICQSVTEITESESDPD
PEVESEDDSTSVEDVDPPTTYYSIIGGGLRMNFGFTKCPQIKSISESADGNTVNARLSS
VSPGQGKDSPAITHEEALAMIKDCEVSIDIRCSEEEKDSDIKTHPVLGSNISHKKVSYEDII
GSTIVDTKCVKNLEFSVRIGDMCKESSELEVKDGFKYVDGSASKGATDDTSLIDSTKLK
ACV 
Note: the first 3 amino acids (colored purple) in the sequence are slightly modified to 
allow for a NcoI cut site at the beginning of the gene. The true wild-type sequence is MP- 
instead of AMA-. I will refer to this sequence as WT throughout my thesis. The 80th 
residue, which is a tyrosine, is bolded and underlined. 
 
Table 1.2. vCCI Protein Characteristics for wild-type and each vCCI mutant used in 
experiments. 
Characteristic WT Y80A 13 aa N-term trunc 
Amino Acids 243 243 230 
Molecular Weight 26174 Da 26082 Da 24938 Da 
Theoretical pI 4.51 4.51 4.51 
Extinction Coefficient 6460 M-1cm-1 4970 M-1cm-1 6460 M-1cm-1 
 
Figure 1.2. vCCI structure (PDB: 2FFK). Figure was made in UCSF Chimera.9 
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1.3.3 Therapeutic Potential 
The therapeutic potential of vCCI has been well noted in the literature. Its 
promiscuous binding of chemokines lends itself to use as a drug to potentially treat 
various conditions that are characterized by excessive and chronic inflammation, such 
as traumatic brain injury, asthma, and arthritis. Alcamí, et al. illustrated the ability of vCCI 
to block eotaxin-induced eosinophil infiltration in guinea pig skin by checking eosinophil 
accumulation 2 hours after various mixtures of eotaxin and vCCI were intradermally 
injected in guinea pigs.13 Buatois, et al. showed the efficacy of vaccinia virus (Lister 
strain) vCCI attached to a human IgG1 Fc domain in mice by stopping cell migration to 
locally inflamed tissue in an air pouch model and by interfering with collagen-induced 
arthritis.14 White, et al. showed vaccinia virus (Lister strain) vCCI attached to a human 
IgG1 Fc domain inhibited CC chemokine-induced calcium flux, chemotaxis, and β-
arrestin recruitment in murine primary macrophages and transfected cells.14 Dabbagh, et 
al. demonstrated the ability of cowpox vCCI to treat asthma in mice when administered 
intranasally. They found that vCCI greatly reduced inflammation in the airway and the 
lung parenchyma, while it did not change immune responses systemically (at 
extrapulmonary sites).15  
 
1.3.4 Relevant Mutations in Literature 
In the same paper referenced above, White et al. made mutations to vCCI (which 
was attached to a human IgG1 Fc domain) based on previously published structural 
data15 by Zhang, et al. to see how that would change its ability to reduce chemokine 
signaling. The mutations Y80A, R89A, D141A, D141L, D141R, E143A, E143K, E143R, 
V185A, Y217A, and Y217N were all made and tested.16 15 nM vCCI (WT or mutants) 
was pre-incubated with 5 nM RANTES for 2 hours before being added to cell culture. 
WT vCCI-Fc produced only 38% of the response of RANTES by itself. They expected 
and found the charge swap mutants of 143 to have a complete (>95%) loss of function. 
Mutations to 141 reduced vCCI’s function. The mutations made to 217 worsened vCCI’s 
function. V185A somewhat improved the function of vCCI. They expected both R89A 
and Y80A to improve the ability for vCCI to block chemokine signaling.16 They thought 
that removing the relatively bulky Y (80th residue) and R (89th residue) from the binding 
pocket would improve binding. R89A did indeed enhance vCCI’s function. However, 
Y80A showed complete loss of function. They rationalize that Y80A must make a critical 
contact for binding with K48 in RANTES.16 
Arnold, et al. studied the following mutants of mousepox vCCI (referred to as 
EVM1 in the paper): Y69R, S134R, N136W, S171W, S171Y, I173Y, I173R, and Δ51-
65.17 Using SPR (Surface Plasmon Resonance) with human MIP-1α, they found L125R 
improved binding by 1.7x and E17R & K138Y had only a slightly smaller KD than WT. All 
the other mutants worsened binding, especially I173R and Δ51-65. They expected the 
Y69R mutant to be a worse binder because it places R near a positively charged residue 
in the chemokine.17 Y69R, comparable to Y80 in rabbitpox, reduced binding affinity by 
52x, giving an apparent KD of 1.50 nM ± 0.30 nM compared to 0.029 nM ± 0.011 nM for 
WT. It is noted that the on rate was not affected by this mutation. 
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1.4 Summary 
1.4.1 Summary of vCCI:vMIP-II Complex 
The complex between vCCI and vMIP-II was investigated by our group because 
they both evolved to be complimentary to each other. vCCI evolved to tightly bind 
chemokines, while vMIP-II evolved as a chemokine analog. vCCI binds vMIP-II with a 
very high affinity, shown to be 0.06 nM ± 0.006 nM through competitive fluorescence 
experiments in our lab by Nai-Wei Kuo.18 This complex takes two viral proteins evolved 
to promiscuously bind their targets, chemokines for vCCI and chemokine receptors for 
vMIP-II, and shows how well they both do what they have evolved to do. Previously, our 
group carried out NMR experiments to determine which regions of the proteins are 
important for binding, as evidenced by chemical shift change upon complex formation.18 
vCCI experiences the largest chemical shifts upon vMIP-II binding in the residues in the 
80’s, 140’s, and 190’s, with other notable shifts in the 30’s, 170’s, 180’s, and 220’s 
regions. Many of these regions are in β-sheets in vCCI’s binding pocket. The acidic loop 
in the 50’s to 70’s region that is shown to be involved with binding by molecular 
dynamics simulations are hard to see by NMR due to their flexibility.18 Negatively 
charged residues D141 and E143 are important for binding. For vMIP-II, NMR chemical 
shift changes upon vCCI binding are the largest for its N-loop region and two of its β-
sheets, corresponding to residues in the 10’s, 30’s and 50’s regions. 
 
Figure 1.3. The vCCI:vMIP-II complex after 1 microsecond of MD simulation, performed 
by Michael Colvin. Presented in Figure 4A of our previously published paper.18 vMIP-II is 
shown in blue and vCCI is shown in red. The figure was made in UCSF Chimera.9 
 
1.4.2 Hypothesis and Techniques Used 
For this master’s degree work, we decided to explore the interesting effect of the 
Y80A mutation in vCCI. Our group’s previous structural results indicated the vCCI Y80 
was located at the base of the acidic loop, near the binding site of chemokine ligands.10 
The tyrosine at that location could possibly be sterically impeding the chemokine’s 
20 
 
arginine near that location in the binding pocket. The results of Arnold, et al. supported 
this idea through their Y69R mutation in mousepox leading to lower affinity of the 
vCCI:chemokine complex.10 Their mutant both maximized steric and charge repulsion at 
that site. Additionally, Beck, et al. showed that MCP-1 K49A (a chemokine residue close 
to the 80th position of vCCI when bound) increased affinity to vCCI by 3x.19 This all led to 
White, et al. mutating the tyrosine at the 80th position to alanine, hypothesizing that this 
would increase vCCI binding affinity through lowering steric repulsion with the 
chemokine.16 However, they found the opposite: the Y80A mutation caused vCCI to lose 
function. They did not have a solid reason for why this was the outcome, which intrigued 
our collaborator, Dr. Michael Colvin. Through analysis of his molecular dynamics (MD) 
simulation data, he came up with the hypothesis that Y80 could be holding the acidic 
loop open, exposing the binding site of vCCI. Mutating the bulky Y80 to a smaller alanine 
could destabilize the loop position. His and his graduate student Lauren Stark’s 
simulation data on this indicates that the Y80A mutation causes the loop to collapse onto 
the β-sheets of the binding site. Their simulation results are shown in Figures 1.4 to 1.6. 
Figure 1.4 shows vCCI WT after 1 microsecond of simulation time, with the loop open. 
Figure 1.5 shows vCCI Y80A after both 1 microsecond and 2 microseconds of simulation 
time. At 1 µs, the loop is partially collapsed, having some interactions with the β-sheet 
below, especially R149. At 2 µs (and prior), the loop is fully collapsed onto the β-sheets 
below and P58 on the loop is in a pocket formed by the β-sheets. 
 
Figure 1.4. vCCI WT after 1 microsecond of simulation time, performed by Lauren Stark. 
Y80 is colored in yellow, with its side chain showing. The figure was made in UCSF 
Chimera.9 
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Figure 1.5. vCCI Y80A after (A) 1 microsecond of simulation time and (B) 2 
microseconds of simulation time, performed by Lauren Stark. At 1 microsecond, the 
acidic loop is partially collapsed. It fully collapses and stays stably down up to 2 
microseconds (this is the longest simulation to date). The 80th residue alanine is in 
yellow with its side chain showing in both (A) and (B). Interacting residues are shown in 
orange with their side chains showing in both (A) and (B). In (A), E63 on the loop is 
shown near R149 on the β-sheet below. In (B), P58 on the loop is in a pocket in the β-
sheets. The figure was made in UCSF Chimera.9 
 
During their vCCI Y80A simulations, they have seen the floppy N-terminus interact 
with the acidic loop when it collapses, in some cases assisting to keep it open. This is 
shown in Figure 1.6, below. D73 and D75 are seen in close proximity to the positively 
charged N-terminus. We were interested in whether the N-terminal tail contributes to 
keeping the loop open. For these reasons, we decided to make both the Y80A mutant 
and a 13 amino acid (12 amino acids if considering the true WT sequence, see section 
1.3.2 for further explanation) N-terminal truncation mutant to test experimentally. 
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Figure 1.6. vCCI Y80A after 500 nanoseconds (0.5 microseconds) of simulation time, 
performed by Lauren Stark. The 80th residue alanine is in yellow with its side chain 
showing. D73 and D75 (colored orange) and seen interacting with the positively charged 
N-terminus (colored green). The figure was made in UCSF Chimera.9 
 
 I made the Y80A and 13 aa N-terminal truncation mutants and expressed them in 
E. coli. I optimized purification protocols. Then I used CD, NMR, and ITC to test them 
(except the truncation mutant has not yet been tested). The proteins’ secondary 
structure and stability were tested by doing a temperature ramp of vCCI WT and vCCI 
Y80A. NMR HSQC spectra were obtained for both vCCI WT and vCCI Y80A, and 
changes in chemical shift were analyzed to see changes in the chemical environment of 
various residues. ITC was used to perform binding experiments of vCCI WT and vCCI 
Y80A with vMIP-II to determine if there was a change in KD with the mutant. 
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Chapter 2 
 
Creation of Mutants and Protein Expression & Purification 
 
2.1 vCCI Mutations 
As discussed earlier, the two mutants of vCCI produced were vCCI Y80A and 13 
aa N-terminal truncation vCCI (referred to as 13 aa Nt-trunc vCCI from here on out). 
Two-step PCR was used to create both mutants. While usually one-step PCR would be 
fine for an N-terminal truncation mutation in DNA, it was more complicated in this case 
due to the 7 poly-serine protein sequence in the desired truncation region (see Section 
1.3.2 for the vCCI protein sequence). It is difficult to not get slippage of the primer 
needed for that region in a one-step PCR. For point mutations, two-step PCR or 
Quikchange® can be used. Two-step PCR was chosen as the strategy for both mutations 
and they were both successful. Below, the primers and strategies used for the Y80A 
mutation are shown in Table 2.3 and Figure 2.2, respectively, and for the 13 aa Nt-trunc 
mutation, they are shown in Table 2.4 and Figure 2.3, respectively. Below, the 
troubleshooting and optimization that led to the optimal conditions for each mutation are 
discussed. 
 
Figure 2.1. Vector layout for vCCI gene inside of the pET 32a vector. 
 First, the possible regions that could be selected in the vector and gene had to 
be analyzed when designing the primers. See Figure 2.1 for the layout of the vector 
used and for reference when discussing primer design. The primers on the exterior of 
the gene (1 and 4 in the below tables and figures) were easier and could wait to be 
decided on until the end because there was a large amount of length from which to 
choose. Thus, the mutational primers (the primers that will actually be causing the 
mutation on the interior of the gene), which could not easily be changed, were the 
primary focus. Once the mutational primers are designed, it is simple to find good 
candidates for the exterior of the gene. To save some money and hassle, primers #1 
and 4 were designed to be the same for both mutations because vCCI was in pET 32a, 
so the sequences around the gene remained the same. Restriction enzyme cut sites 
available around the gene were checked using the NEBcutter V2.0 tool. It is ideal that 
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two different enzymes are used and that there is only one cut site for each. To check if 
there was a compatible buffer for a given set on enzymes, the NEB RE Digest tool was 
utilized. Once the cut sites are known, the exterior primers must be far enough away 
from the gene that the desired cut sites are included in the PCR products. This allows for 
the PCR product to be cut and ligated back into the vector. 
Primer lengths of about 20 bp were aimed for, with a C or G on the ends of the 
oligo to help it better bind to the template DNA. Then, the oligo’s melting temperature 
(Tm) was checked using the NEB Tm Calculator with Phusion High-Fidelity DNA 
Polymerase (HF Buffer) selected. The desired result for the melting temperatures was 
for them to be between 55°C and 65°C and for all the primers to be within about 5°C of 
each other. Then, the IDT DNA Analyzer tool was utilized to check that the most 
favorable hairpin Tm was below the primer’s melting temperature by 15°C or more. Also, 
it could cause problems if self- or hetero-dimerization of the oligos are too favorable. All 
the combinations of primers in the reactions needed to be checked in IDT’s tool. 
 For each PCR, gradient PCRs were done to test a variety of annealing 
temperatures. First, for the 1st step PCRs, 4 separate reactions were done with 
annealing temperatures from approximately 58°C to 66°C, at increments of 2°C, using 
the DNA polymerase Taq pol at first to scout inexpensively. The following program was 
used on the Eppendorf Mastercycler® Gradient thermocycler:  
 
Table 2.1: Initial method for Taq pol scouting 1st step PCR reactions. Tubes were placed 
in columns 1 (58.1°C), 4 (60.7°C), 5 (62.5°C), 6 (64.6°C) and 7 (66.7°C). 
Step Temp (°C) Duration (min:sec) Step Explanation 
1 95 1:00 Initial denaturation 
2 95 1:00 Denaturation 
3 66 (G=7.8) 1:00 Annealing 
4 72 1:00 Elongation 
5 72 2:00 Elongation to finish any 
left-over fragments 
 
Sizes were checked under UV light after reactions were run on 1.2% agarose 
gels containing EtBr at 100 V for 40 minutes. All reactions worked except the truncation 
reaction results for the 1st Step PCR (a) (see Fig 2.2) couldn’t be visualized on the gel. 
For the Y80A reactions, 58°C worked best as the annealing temperature. Whereas, for 
the truncation reaction that could be seen on the gel, 62.5°C worked best. Phusion pol 
(higher quality DNA polymerase) was used going forward because there was a good 
idea of what annealing temperatures would work. With Phusion, the following method 
was used: 
 
 
Steps 2-4 
Repeat 28x 
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Table 2.2 Phusion method for 1st step PCR reactions. Tubes were placed in columns 1 
(58.1°C) for Y80A reactions and 5 (62.5°C) for truncation reactions. 
Step Temp (°C) Duration (min:sec) Step Explanation 
1 98 0:30 Initial denaturation 
2 98 0:10 Denaturation 
3 66 (G=7.8) 0:45 Annealing 
4 72 1:00 Elongation 
5 72 10:00 Elongation to finish any 
left-over fragments 
 
 
All the reactions were the expected size. The reaction tubes were PCR purified. 
Then, 35 ng of DNA from each of the two 1st step reactions for each mutant were 
combined. The first part of the 2nd step PCR was elongation of the PCR products, which 
overlap each other (see figures 2.1 and 2.2). This was done by repeating the Phusion 
method above, but with no primers present, an annealing temperature of 62°C with no 
gradient, and only repeating Steps 2-4 10x. After that finished, primers were added and 
the Phusion method was done again (still with an annealing temperature of 62°C), but 
this time repeating Steps 2-4 30x, like normal. The truncation mutant was confirmed to 
be the right size, but the Y80A mutant was not. This was troubleshooted by repeating 
the 2nd step PCR with an annealing temperature gradient, trying 52°C, 54.2°C, 56°C, 
58.1°C, 60.2°C, 64.5°C (having already tried 62°C). The annealing temperature that 
worked was 56°C, with none of the other temperatures resulting in the correct size of 
PCR product. 
 
Table 2.3. vCCI Y80A primers (numbers correspond to Figure 2.2). Tm is based on NEB 
Tm Calculator with Phusion High-Fidelity DNA Polymerase (HF Buffer) selected. 
vCCI Y80A 
Primer Sequence (5’ — 3’) Length (bp) Tm (°C) 
1 CTG TTC AAA AAC GGT GAA GTG 21 62 
2 GAT GAT GGA GTA AGC AGT GGT AG 20 62 
3 CTA CCA CTG CTT ACT CCA TCA TC 20 62 
4 GAT CTC AGT GGT GGT GGT G 19 62 
 
Steps 2-4 
Repeat 30x 
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Figure 2.2. vCCI Y80A mutation strategy. The numbered primers are listed in Table 2.3. 
The red X’s correspond with the Y80A mutation introduced into the DNA through the 
mutational primers. The arrows at the ends of the primers indicate direction of 
polymerization—they are not overhangs. The DNA segment shown above is a zoom in 
on the Tags and vCCI gene region of the vector. The cut sites that will be used later on 
are within the PCR product. 
 
Table 2.4. N-term 13 aa truncation vCCI primers (numbers correspond to Figure 2.3). 
Tm is based on NEB Tm Calculator with Phusion High-Fidelity DNA Polymerase (HF 
Buffer) selected. 
N-term 13 aa truncation vCCI 
Primer Sequence (5’ — 3’) Length (bp) Tm (°C) 
1 CTG TTC AAA AAC GGT GAA GTG 21 62 
2 GAG GAC TTG TCG TCG TCG TC 20 65 
3 GAC AAG TCC TCA TCC TCG TGT AC 23 64 
4 GAT CTC AGT GGT GGT GGT G 19 62 
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Figure 2.3. vCCI 13 aa N-term truncation mutation strategy. The numbered primers are 
listed in Table 2.4. The green and red portions are the areas that were on either side of 
the area that was truncated. The arrows at the ends of the primers indicate direction of 
polymerization—they are not overhangs. The primers that have a longer red or green 
overhang (as in primer #2 and #3) without an arrow on that end are actual overhangs. 
The DNA segment shown above is a zoom in on the Tags and vCCI gene region of the 
vector. The cut sites that will be used later on are within the PCR product. 
The PCR products and pET 32a vector were all double digested with BglII and 
XhoI in NEB Buffer 3.1 (the only buffer with 100% activity for both restriction enzymes on 
NEB Double Digest Finder) at 37°C. SAP was added to the cut pET 32a vector at the 
end of the digest reaction to avoid vector reclose using ligation. The cut bands were gel 
extracted and purified. The cut mutant PCR products were combined with the cut vector 
(in a 9:1 ratio based on their concentration, adjusted for their size: 
𝑛𝑔
(µ𝐿 ∗ 𝑏𝑝)⁄ ) and 
were ligated together by T4 ligase for 1 hour at room temperature. The resulting ligated 
2nd step PCR products in pET 32a were transformed into XL1 Blue cells, plated and 
incubated at 37°C, then single colonies were chosen to grow up by shaking in LB with 
antibiotic they have resistance to for 16 hours at 37°C, then miniprepped. The resulting 
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minipreps were sequenced at the UC Berkeley DNA Sequencing Facility with either T7 
promotor or reverse primers. They were successful. The final PCR conditions that 
worked are listed in Table 2.5. 
Table 2.5. Optimized annealing conditions for Y80A and truncation mutants’ PCRs. 
PCR Step Y80A (°C) 13 aa Nt-trunc (°C) 
1 (a) 58 62.5 
1(b) 58 62.5 
2 56 62 
2 (after primer 
addition) 
62 62 
 
2.2 Protein Expression 
vCCI WT and mutants were contained in the pET 32a expression vector, which 
has ampicillin resistance. vMIP was contained in a pET 28a expression vector, which 
has kanamycin resistance. A fresh transformation was done with Escherichia coli BL21 
(DE3) (Novagen) competent cells, then plated onto 100 µg/mL ampicillin or 50 µg/mL 
kanamycin agar plates and incubated at 37°C for 12 hours. Starter cultures were made 
with 7 mL LB with either 100 µg/mL ampicillin or 50 µg/mL kanamycin, and 15 colonies 
from the corresponding antibiotic plate. These were shaken at 37°C for 2 hours before 
being put in 1 L of either warmed LB (14N) or M9 minimal media (with the sole nitrogen 
source being 15NH4Cl), with the same antibiotic concentration as the starter cultures. The 
media was shaken at 37°C until the OD600 of the cells was approximately 0.7. At that 
point, 0.7 mM IPTG final concentration was added to induce the cells. They expressed 
for 20 hours at 22°C while shaking. Afterward, the media was centrifuged at 4400 x g for 
10 minutes at 4°C. The supernatant was decanted, then the pellet was resuspended in 6 
M Guanidine HCl, 200 mM NaCl, 50 mM Tris, pH 8.0. 
 
2.3 Protein Purification 
In all cases, the resuspended pellets with approximately 10 mM benzamidine (a 
protease inhibitor) were passed through a French Press three times to lyse the cells 
before being centrifuged at 27000 x g for 1 hour at 4°C. The supernatant (which 
contained the protein of interest due to its being soluble in the guanidine buffer) was 
decanted into polypropylene tubes and allowed to sit at -20°C overnight to allow for 
further separation of cell debris. The tubes were spun down for an additional 15 minutes 
at about 3400 x g at 4°C to further pellet cell debris. See each subsection below to see 
the rest of the purification protocol for vCCI (WT and mutants) and vMIP-II. SDS-PAGE 
was used throughout the expression and purification process to monitor the protein size. 
NMR HSQCs for 15N-labeled samples or echo11 for 14N samples were obtained at the 
end of the purification process to confirm proper folding. 
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2.3.1 vCCI WT and Mutants 
This protocol is an adaptation of the protocol used in our previous paper.18 The 
protein construct has both a thioredoxin (Txn) tag and a 6x-His tag at its N-terminus with 
a DDDDK cut site in between the tags and the protein of interest (vCCI), so the tags can 
later be cleaved off by enterokinase (EK). The His tag is in the middle of the Txn tag and 
vCCI, so to help expose the His tag, the supernatant was reduced with 15 mM βME for 
two hours at room temperature before passing through a home-packed gravity nickel 
column. The nickel column was equilibrated in the same lysis buffer and 15 mM βME. 
Subsequently, the protein supernatant was passed through the column 2x. Then, the 
column was washed with 10 column volumes of 6 M Gnd-HCl, 200 mM NaCl, 50 mM 
Tris, pH 8.0, 15 mM βME, followed by 10 column volumes of 6 M Gnd-HCl, 200 mM 
NaCl, 80 mM NaOP, pH 7.0, 15 mM βME. The protein stuck to the column was then 
eluted off with 6 M Gnd-HCl, 200 mM NaCl, 60 mM NaOAc, pH 4.0. The fractions 
identified by absorbance at 280 nm to have the majority of eluted protein were collected 
in a polypropylene tube, then βME was added to bring its concentration to 25 mM. A 
small stir bar was put in the tube, then stirred at room temperature for one hour before 
stirring at least 12 hours at 4°C. This step was needed to ensure all disulfides were 
reduced in the protein (one disulfide in Txn and four in vCCI).  
The protein was drip refolded into 20x volume refold buffer (550 mM L-Arg HCl, 
400 mM sucrose, 9.6 mM NaCl, 0.4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 3 mM GSH, 0.3 
mM GSSG, 50 mM Tris, pH 8) that was cooled by ice and within a 4°C fridge 
beforehand. The protein was allowed to refold for at least 24 hours at 4°C while stirring. 
Note that long reduction and refold times, low temperatures, and greater than normal 
concentration of redox pair (glutathione) proved to be essential for proper refolding of the 
protein. After refolding, the solution was put into 10 kDa MWCO dialysis bags and 
dialyzed into 4 L of 20 mM Tris, 2 mM CaCl2, 200 mM NaCl, pH 7.4 three times at 4°C. 
On the third dialysis, EK was added to the bags for 20 hours to cleave the tags off. 
Cutting is visible by SDS-PAGE, with vCCI running at about 35 kDa and the tags running 
at about 17 kDa. 
After cutting, the protein was dialyzed into the buffer used for SEC: 20 mM Tris, 
200 mM NaCl, pH 7.4 (very similar to the cutting buffer, just without the CaCl2). The 
protein was then concentrated about 55x because it was dilute to allow for better 
refolding, but SEC resolution depends on loading only a small volume onto the column. 
Each run was done by loading 5 mL of concentrated protein onto a HiLoad® 16/600 
Superdex® 75 prep grade (GE Healthcare) SEC column on the AKTA system. This 
column has a column volume of 120 mL. Large molecules come through an SEC column 
first because they have a shorter average path length through the column. Smaller 
molecules have a larger path length because they enter pores in the resin while traveling 
down the column. All runs were performed by equilibrating the column with 96 mL of 
SEC buffer at a 0.8 mL/min flow rate and 0.5 MPa pressure alarm. vCCI comes out at 
about 70 mL after injection. The protein is stable to store at 4°C for long periods of time. 
vCCI was concentrated in an Amicon concentrator with a 10 kDa filter prior to ITC 
experiments. 
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2.3.2 vMIP-II 
This protocol is an adaptation from the protocol used in our previous paper.18 
This protein made from the pET 28a construct has both a SUMO tag and a 6x His tag at 
its N-terminus which are cleaved off by ULP-1 later in the purification process. ULP-1 
cleaves conditional upon SUMO having a properly folded tertiary structure. Home-
packed gravity nickel columns were equilibrated in the same buffer used when lysing the 
cells. The protein supernatant was passed through the column 2x. Then, the column was 
washed with 10 column volumes of 6 M Gnd-HCl, 200 mM NaCl, 50 mM Tris, pH 8.0, 
followed by 10 column volumes of 6 M Gnd-HCl, 200 mM NaCl, 80 mM NaOP, pH 7.0. 
The protein stuck to the column was then eluted off with 6 M Gnd-HCl, 200 mM NaCl, 60 
mM NaOAc, pH 4.0. The fractions identified by absorbance at 280 nm to have the 
majority of eluted protein were collected in a polypropylene tube, then βME was added 
to bring its concentration to 10 mM. A small stir bar was put in the tube, then stirred at 
room temperature for 2 hours before drip refolding. The reduction and refolding protocol 
for vMIP is less extensive than for vCCI because vMIP only has 2 disulfide bonds and 
SUMO has zero disulfide bonds (no free cysteines either). The protein was dripped into 
10x refold buffer: 550 mM L-Arg HCl, 200 mM NaCl, 1 mM EDTA, 1 mM GSH, 0.1 mM 
GSSG, 50 mM Tris, pH 8. After dripping was complete, the solution was put into the 4°C 
fridge to refold for at least 12 hours. 
After refolding, the solution was put into 3.5 kDa MWCO dialysis bags and 
dialyzed into 4 L of 20 mM Tris, 200 mM NaCl, pH 8.0 three times at 4°C. On the third 
dialysis, ULP-1 was added to the bags at least 12 hours to cleave the tags off. Cutting is 
visible by SDS-PAGE, with vMIP-II running just above 6.5 kDa and the tags running at 
about 18 kDa. To separate cut vMIP-II from the tags, a 5 mL HiTrap Heparin HP affinity 
column (GE Healthcare) was used on the AKTA system. This was very effective and 
seemed to work better (with higher yields) than a native nickel column. It is necessary to 
remove the tags before using a C4 column because the tags and vMIP-II elute off the C4 
column at the same acetonitrile concentration. The protein was dialyzed into 4 L of 50 
mM Tris pH 7.4. The Heparin column was equilibrated with 10 column volumes of 50 
mM Tris pH 7.4 buffer before the dilute protein was added to the column via a 110 mL 
external loop at a rate of 5 mL/min with an alarm pressure of 0.5 MPa. Once all the 
protein was loaded, the Tris concentration and pH stayed constant while there was a 
gradient from 0 to 1 M NaCl. Salt knocks protein off in the order of least affinity to most 
affinity for heparin. vMIP-II comes off the column at around 50% B (500 mM NaCl), while 
the tags come off near the beginning of the gradient (at low salt concentration), 
separating them very well. 
For the benefit of removing salt and getting the protein in the stable form of 
lyophilized powder, a C4 (Vydac) column with a 20 mL column volume was used on the 
AKTA system as the final purification step. The post-Heparin fractions needed to be 
dialyzed into lower salt (<100 mM NaCl) before running on the C4. One dialysis into 4 L 
20 mM Tris, 80 mM NaCl, pH 8.0 was sufficient. The protein was then prepared for 
loading by centrifuging the sample at 3400 x g for 10 minutes at 4°C. Afterward, 0.2% 
TFA was added to the sample, checked by pH paper to be around pH 1-2, then 10% Acn 
(stock containing 0.1% TFA also) was added. The C4 column was equilibrated with 4 
column volumes of 10% Buffer B (10% Acn/90% H2O, 0.1% TFA) at a rate of 5 mL/min. 
Buffer A is H2O, 0.1% TFA and Buffer B is Acn, 0.1% TFA. The acid is necessary for the 
proteins loaded not to stick too hard to the column, giving them the ability to be eluted by 
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increasing the concentration of acetonitrile. The samples were loaded onto the column 
through an external loop by pushing 1.5x the volume of protein in the loop through it with 
10% B. The first gradient in the program is from 10% B to 28% B at 5 mL/min, then the 
rate is dropped to 2 mL/min while going on a gradient from 28% to 36% B over 4 column 
volumes. The sample should already be very pure at this point and should come off at 
about 34% B. The post-C4 fractions can be lyophilized on a Labconco freeze-dry system 
and then stored at room temperature, away from light. When preparing for various 
experiments, the powder should be taken up in 20 mM NaPi (or similar) pH 2.5. It will 
dissolve really easily and then can be diluted into other buffers as needed. Aggregation 
is a real problem in higher pH buffers, so always take up the powder in pH 2.5 buffer 
first. See more discussion about this in Section 3.3.1 (ITC Theory and Method).  
 
2.4 Discussion & Future Directions 
These methods can be further improved by testing more expression conditions, 
IPTG concentrations, and different expression systems. Notably, vMIP-II has some small 
degradation post-ULP-1 cutting (shows up just below 6.5 kDa on SDS-PAGE) which can 
be separated by the Heparin column, but it does lower the overall yield. A different 
tag/expression system may help prevent this issue. Also, moving through the purification 
process as quickly as possible lowers degradation as well. Anna Nguyen, Ph.D. 
graduate from the P. LiWang Group in 2017, noted that expression in the pET 32a 
expression vector and subsequent cutting with EK chopped the protein up much worse. 
More vCCI mutants are needed to further test our hypotheses. Some of these 
additional mutants are already made in DNA with the help of Kathryn Fischer, a current 
Ph.D. student in the P. LiWang Group at UC Merced. The additional mutants focus on 
adding a Q to the N-terminus in order to later cyclize the Q and thus eliminate the 
positive charge of the N-terminus. Double and triple mutants with Y80A, truncations, and 
Q0 are also of interest going forward with this project. I suspect that the purification 
protocol I describe above will continue to work for these new mutants of vCCI. 
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Chapter 3 
 
Theoretical Background of Techniques & Results 
 
3.1 Circular Dichroism 
3.1.1 Theory and Method 
Circular dichroism (CD) measures the difference in absorbance of left- and right-
polarized UV light. Thus, to have a signal, the molecule must absorb them differently, 
indicating the molecule must be chiral or at least in a structured environment. CD can be 
used to detect tertiary structure via aromatic side chains in the near UV range (250 – 
350 nm), or much more commonly, secondary structure via backbone amide bonds in 
the far-UV range (170 – 250 nm).20 β-sheets have a characteristic minimum at 
approximately 215 nm.21 Whereas, α-helices have two minima at about 210 and 220 nm. 
A random coil has an entirely different profile, with a minimum around 195 nm and a 
maximum near 210 nm. Both β-sheets and α-helices have maxima around 190 nm, in 
contrast. However, it is difficult to see in that range because it tends to get noisy from 
buffer components that absorb near that area. The noise level depends on what buffer 
conditions are used; low salt is optimal. 
The experimental results shown in Section 3.1.2 were obtained on a Jasco J-
1500 Circular Dichroism Spectrophotometer. A 25°C to 95°C temperature ramp was 
performed on 15 µM samples of vCCI WT and vCCI Y80A in 20 mM NaPi, 100 mM 
NaCl, pH 7.0. The temperature gradient was 1°C/min, with 215 nm monitored 
continuously (data collected every 0.2°C). A full spectrum (260 – 190 nm) measurement 
was taken every 10°C. All graphs presented in Section 3.1.2 were generated using the 
Origin software package. The data was normalized based on the CD ratio between the 
vCCI WT and vCCI Y80A at the isodichroic point for both of them at 209 nm (where all 
the curves from various temperatures intersect). Thus, the magnitude at 209 nm is 
based upon the concentration of the sample, not the fold of the protein. The ratio was 
0.93, small enough that it can be attributed to absorbance error and/or other errors in 
transferring volumes for the dilutions. Thanks to Prof. Shahar Sukenik for assistance in 
processing the data shown below. 
 
3.1.2 Results and Discussion 
In Figure 3.1, the far-UV CD spectrum of vCCI WT and vCCI Y80A are overlaid 
at the beginning and end of the temperature ramp from 25°C to 95°C. The spectrum of 
each before and after the temperature ramp is near identical, suggesting similar folded 
and unfolded states. At 25°C, they both have a minimum at about 215 nm (marked by 
the grey vertical line), the characteristic minimum corresponding to β-sheets. The 95°C 
spectra look like what would be expected for unfolding.22 The minimum is no longer at 
215 nm and is shifted to lower wavelengths. There is noise near the 190 nm area, so the 
true minimum may be masked by the buffer noise. 
Figure 3.2 shows the signal at 215 nm for both vCCI WT and vCCI Y80A 
throughout the temperature ramp. The less negative the θ at 215 nm, the less β-sheet 
structure present in the sample. As the temperature increases, so does the ellipticity at a  
33 
 
 
Figure 3.1. Far-UV CD spectrum of vCCI WT (in black) and vCCI Y80A (in red) overlaid 
at the beginning and end of a temperature ramp from 25°C to 95°C. The grey vertical 
line on the graph is at 215 nm (characteristic minimum corresponding to β-sheets). 
 
 
Figure 3.2. Ellipticity at 215 nm of vCCI WT and vCCI Y80A over the course of a 
temperature ramp from 25°C to 95°C. Note the scale is changed from Figure 3.1. The 
black and red vertical lines on the graph are at the melting temperature values of vCCI 
WT and vCCI Y80A, respectively. Data points are shown, with trendlines presented as 
solid lines. The adjusted R2 is 0.99178 and 0.99360 for the vCCI WT and vCCI Y80A 
fitted line, respectively. 
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constant slope, until near 70°C, a more rapid (larger slope) transition begins. The 
temperature at which there is an inflection point of the curve (where the second 
derivative is equal to 0) is the melting temperature (Tm) of the protein. The red and black 
vertical lines on the graph show the Tm of vCCI Y80A and vCCI WT, respectively. They 
are also tabulated in Table 3.1. The Tm of vCCI Y80A is 6.1°C lower than vCCI WT, 
indicating the point mutation significantly destabilizes the protein, though both are still 
quite stable, with melting temperatures above 70°C. 
 
Table 3.1. Melting temperatures of vCCI WT and Y80A found by CD 
Protein Tm (°C) 
vCCI WT 79.7 ± 0.6 
vCCI Y80A 73.6 ± 0.2 
 
I hypothesized that vCCI Y80A may actually stabilize the protein if the floppy 
acidic loop does indeed come down and make contacts with the β-sheets in the binding 
pocket. This hypothesis was proven wrong by the results of this experiment. It is really 
interesting that the CD spectra are so similar between the WT and mutant, but they have 
substantially different melting temperatures. 
 
3.2 Nuclear Magnetic Resonance 
3.2.1 Theory and Method 
NMR stands for Nuclear Magnetic Resonance and uses radiofrequency to excite 
spins in magnetically active nuclei. Before excitation, the magnetic moments of the 
nuclei are randomly oriented. Nuclei with nuclear spin quantum numbers of I = ½, such 
as 1H, 13C, 15N, and 31P, are all commonly used in NMR because they have only 2 
energy levels (given by 2I + 1).23 This makes data less complicated to interpret. Of the 
nuclei listed, only 1H and 31P are naturally abundant. To isotopically label with 13C and 
15N, the protein needs to be expressed with media where these isotopes are the sole 
source of the atom. 
HSQC (Heteronuclear Single Quantum Coherence) spectra were collected. This 
technique relies on INEPT (Insensitive Nuclei Enhanced by Polarization Transfer) steps 
through J coupling, which allows for nuclear spin polarization transfer from H to another 
nucleus, usually to 13C or 15N (which the protein would need to be labelled with ahead of 
time).24 In our case, 15N labeling was used. The resulting spectra have axes of the 
chemical shift δH in ppm and the chemical shift of the other nucleus in ppm also. Each 
pair of a unique H bonded to the other nucleus is a peak on the spectrum. This is 
commonly referred to as a protein ‘fingerprint’. Peaks shift differently based on their 
chemical environment, so if a protein is folded, distinct peaks should be seen. Chemical 
shifts are calculated as follows, with 𝜐𝑟𝑒𝑓 corresponding to DSS: 
δ =
(𝜐𝑜𝑏𝑠 −  𝜐𝑟𝑒𝑓)
𝜐𝑠𝑝𝑒𝑐𝑡
∗ 106 
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NMR spectra were obtained on a 600 MHz Bruker Avance III spectrometer with 
four channels and a TCI cryoprobe. NMR experiments were done at 30°C and in a 
shaped tube to help reduce the noise from salt in the buffer. The buffer used was 20 mM 
NaPi, 100 mM NaCl, pH 7.0. Samples were prepared by adding 330 µL protein sample, 
19 uL 99.8% D2O, and 1.5 uL 5 mM DSS in D2O.  
 
3.2.2 Results and Discussion 
Both vCCI WT and Y80A look folded due to distinct peaks above 9 ppm HN and 
low smearing down the middle of the spectra. The vCCI WT spectrum is very similar to 
known vCCI spectra and the vCCI Y80A spectrum overlays the WT spectrum nicely. It 
matches most peaks and only has some significantly shifted. These shifted peaks are 
key to understanding the difference in structure, which influences function. It is clear that 
the largest shifts (Y80A peak not touching the WT peak) are in I51, Y80, Y81, S82, I83, 
F92, G93, T95, K96, and S145 (not totally exhaustive). There are notable shifts (Y80A 
peak touching WT peak, but is offset from it) in V28, C97, S106, L139, E143, and V144 
(not totally exhaustive). The NMR samples were only 15N-labeled; to get better 
assignments, simultaneous 15N- and 13C-labeling is necessary. Some of the unassigned 
peaks moved substantially, but the identity of the peak was not known for certain. 
 
Figure 3.3. NMR HSQC spectrum of vCCI WT is shown in pink, with the HSQC 
spectrum of vCCI Y80A in blue overlaid on top. The colors combine when peaks overlap, 
making those areas purple. Many vCCI WT (pink) peaks are assigned, with the residue 
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number written next to peaks. The assignment data used to compare to these spectra 
can be found at BMRB: 6809. These are hard copy plots made in NMR Draw, then 
overlaid. 
 
Figure 3.4. Residues that change chemical shift in the vCCI Y80A mutant mapped onto 
vCCI WT. vCCI WT (PDB 2FFK) is colored red. Residues that are highlighted in green 
have a moderate chemical shift perturbation (Y80A peak touching WT peak, but is offset 
from it) and yellow have a large chemical shift perturbation (Y80A peak not touching the 
WT peak), as evident in Figure 3.3, above. The figure was made using UCSF Chimera.9 
 
The large (colored yellow) and moderate (colored green) shifts are mapped in Figure 
3.4. It is to be expected that the residues right around the point mutation (such as 80-83) 
would have large shifts. However, some of these residues have also been found to shift 
substantially upon binding vMIP-II. The residues further away from Y80 in the sequence 
that shift are more interesting. The 90’s and 140’s regions are also known to shift a large 
amount upon vMIP-II binding.18 It is supportive of our hypothesis that key binding 
residues on vCCI are shifting upon the Y80A mutation. This suggests that these 
residues are in a different environment, which could possibly be explained by a loop 
making contact with the β-sheets of the binding pocket. 
 
3.3 Isothermal Calorimetry 
3.3.1 Theory and Method 
Isothermal calorimetry (ITC) is a useful tool for obtaining thermodynamic data of 
various interactions and functions by measuring the changes in heat as two molecules 
are titrated together.25 The instrument has a reference cell and a sample cell. The cells 
are kept the same temperature through heating or cooling of the sample cell. The 
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instrument is very sensitive to changes in heat. The raw data is heat rate on the y-axis 
and time on the x-axis. Knowing the concentrations and volumes added allows the x-axis 
to be converted to mole ratio between the titrant and the titrand. The injection peaks 
areas are found through integration after the baseline and integration region are set and 
that becomes the new y-axis. A control is subtracted from the data, either by injection or 
by average area, to subtract out the heat from dilution. The remaining heat is from the 
interaction between the titrant and titrand. The data is fit and the result is what is known 
as a Wiseman Plot. The largest peak areas should be at the beginning of the titration 
and by the end of the titration, if the experiment is set up correctly, all the titrand should 
have reacted and the last few titrant injections should be just heat from dilution that will 
equal 0 after subtraction of the control. The change in heat between the beginning and 
end of the experiment gives you the change in enthalpy, modified to be per mole. The 
stoichiometric ratio (n) is found by the mole ratio when the transition from not fully bound 
to becoming fully bound occurs. The KD is found from the slope of the transition.26 A 
small KD will have a large (steep) slope, whereas a large KD will have a small (gradual) 
slope. 
All ITC data was obtained on a TA Instruments Nano ITC Low Volume 
isothermal titration calorimeter. All experiments were done at 25°C with a stir rate of 350 
rpm. The equilibration step before starting the experiment was set to 10 minutes (600 
seconds). 20 injections, 2.5 µL each, of either 200 µM vCCI WT or 170 µM vCCI Y80A 
were titrated into 20 µM vMIP-II. All experiments were done in 20 mM NaPi, 100 mM 
NaCl, pH 7.0 buffer. The two controls and binding experiment for either vCCI WT or 
vCCI Y80A were all done on the same day to reduce variability. 
The concentration of stock tubes of each protein was determined by the 
absorbance at 280 nm before starting experiments on a given day. The proteins were 
diluted to the desired concentration by mixing with the saved dialysis buffer, so there 
was no difference in buffers. To keep vMIP-II soluble, it had to be kept in 20 mM NaPi 
pH 2.5 buffer prior to dilution on the day of the experiment. The stock was very 
concentrated (1.3 mM) so only a few microliters of it was added to approximately 400 µL 
of the pH 7 buffer used in the experiment. The same ratio of 20 mM NaPi pH 2.5 buffer 
was added to all other solutions used in the experiment for minimal buffer mismatch. 
After dilution, the solutions were degassed for 20 minutes. While degassing, the ITC 
cells were rinsed 3 times with 400 µL of DI water. Once degassing was complete, the 
reference cell was rinsed 3 times with 300 µL of degassed DI water before being loaded 
with 300 µL DI water. This is only done for the first experiment of the day. Any proteins 
involved in the experiment had their absorbance taken immediately prior to loading into 
the cell or syringe to have the most accurate concentrations for data analysis. This is 
especially important for vMIP-II or other chemokines which are prone to aggregation at 
pH 7 buffer conditions. 
The sample cell was rinsed 3 times with 300 µL degassed buffer before being 
loaded with 300 µL of either degassed buffer (for control) or vMIP-II (for control or 
binding experiment). The 50 µL titrating syringe was rinsed at least 3 times with 
degassed buffer before being loaded with either degassed buffer (for control) or 
degassed vCCI WT or Y80A (for control or binding experiment). The loaded titrating 
syringe was submerged into the sample cell and locked into place. The ‘Monitor’ tab on 
the ITC software was watched to see when the system reached equilibrium, then the 
stirring was engaged. Once the system reached equilibrium again, the experiment was 
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started. This two-step equilibration process was recommended to me by Colette Quinn 
at TA Instruments to be potentially useful when dealing with aggregating proteins.  
After every experiment, the sample cell and syringes were washed with 1% 
Contrad-70 solution and rinsed with a lot of DI water. For the sample cell, 500 µL of the 
Contrad solution was added and pipetted up and down twice. Then, it was rinsed 10 
times with 500 µL of DI water. After each of the first 5 washes, the loading syringe was 
rinsed an additional time with DI water to help remove Contrad from the syringe. After 
washing, the sample cell was left with 300 µL of DI water in it. The syringes were rinsed 
in a one-direction fashion by removing the plunger and spraying through the syringe with 
a DI water bottle for a minimum of 30 seconds.  
3.3.2 Results and Discussion 
The vCCI WT ITC data is shown in Figure 3.5 and modelled in Figure 3.6. The 
vCCI Y80A ITC data is shown in Figure 3.7 and modelled in Figure 3.8. Both show 
relatively tight binding to vMIP-II, with vCCI WT having a fitted KD of 1.00 x 10-10 M 
(lower limit of detection) and vCCI Y80A having a fitted KD of 2.99 x 10-8 M. For vCCI 
WT’s KD, we cannot say that it is 1.00 x 10-10 M, but we can say it is less than or equal to 
that value because the lower limit of detection of the ITC for KD is 1.00 x 10-10 M. In all 
experiments involving vMIP-II, vMIP-II was in the sample cell. The vMIP-II concentration 
was kept constant at approximately 20 µM in all experiments with vMIP-II. In all 
experiments involving vCCI WT or vCCI Y80A, they were in the titrating syringe. The 
concentration of vCCI WT used in experiments was approximately 200 µM. The 
concentration of vCCI Y80A used in experiments was approximately 170 µM. The 
concentration of proteins was checked right before loading into the ITC for the most 
accurate experimental concentrations. There was some slight variability noted between 
experiments. I rounded all concentrations presented to the nearest µM value. 
I would have liked to have done the experiments with the same concentration of 
vCCI WT and vCCI Y80A, but due to a slight logistical error, I had to do the vCCI Y80A 
experiment at a slightly lower concentration. Both experiments had all their controls 
done, which were internally consistent, and the vCCI WT and vCCI Y80A experiments 
were independent from each other. Because of this, the data is still interpretable, but the 
magnitudes of heat rates differ between the experiments (see the y-axis values in 
Figures 3.5 and 3.7). Note that the scales of Figures 3.5 and 3.7 differ for this reason. 
The data presented below is a singlet of each binding experiment with two 
controls each. For vCCI WT and vCCI Y80A, the binding experiment and two controls 
were done on the same day to reduce variability as much as possible. The following 3 
experiments were done for each vCCI (WT or Y80A): 
• Binding experiment:  vCCI titrated into vMIP-II 
• vCCI control:    vCCI titrated into buffer 
• vMIP-II control:  buffer titrated into vMIP-II 
The legends of Figures 3.5 and 3.7 describe which curve corresponds to each 
experiment. In both cases, the black curve shows the vMIP-II control and the blue curve 
shows the vCCI control. For the vCCI WT experiment, the binding experiment data is 
shown in green. For the vCCI Y80A experiment, the binding experiment data is shown in 
red. In the upper graph of these figures, the 3 curves are stacked one on top of the 
other, so that each data set can be seen easily. Keep in mind that the baseline values 
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are not different between them (e.g. the corrected heat rate for the vMIP-II control in 
Figure 3.5 is not 1.5 µJ/s, it is actually 0 µJ/s). The curves are artificially stacked on top 
of each other for viewing ease. In the bottom graph of each figure, the curves are 
overlaid so it can be seen how much extra heat the binding experiment releases. The 
unobstructed green (for WT) and red (for vCCI Y80A) peaks for the first many injections 
show the heat change caused by binding events occurring. Later injections cause about 
as much heat as the vCCI controls, indicating no more binding events are occurring—all 
the vMIP-II has already been bound at that point. 
 
 
Figure 3.5. ITC corrected heat rates resulting from approximately 200 µM vCCI WT 
titrated into 20 µM vMIP-II. As described in the legend above, light green corresponds to 
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the binding experiment, blue is the vCCI WT into buffer control, and black is the buffer 
into vMIP-II control. The top graph shows the 3 experiments stacked on top of each 
other and the bottom graph shows them all overlaid. 
 
 
Figure 3.6. vCCI WT binding of vMIP-II modelled using the Independent model in 
NanoAnalyze. The binding experiment (light green) shown above had the vCCI WT into 
Buffer control (blue) subtracted out of it ‘by injection’. The first data point was omitted 
from the fit, which is widely accepted and expected. 
 
The vCCI WT binding experiment data was processed by manually fitting the 
baseline for each peak and selecting 125 second integration regions for injections 1-7, 
100 seconds for injection 8, and then 80 seconds for injections 9-20. The vCCI WT 
control data was processed by keeping the automatically selected baseline and selecting 
300 seconds as the integration region for all peaks. The control peak areas were 
subtracted from the binding experiment ‘by injection’. Usually ‘average area’ subtractions 
are best, but this is only the case if the peak areas are staying constant throughout the 
control experiment. Subtraction ‘by injection’ was used because the control’s peak areas 
had a small linear slope upward, which can be seen if there is a slight buffer mismatch. 
For this reason, the most accurate way to subtract the control from the experiment is to 
do it by injection because the injection peak areas are varying over the experiment in a 
small, but predictable way. The more one buffer is titrated into the other, the more similar 
they become. So, you will see there is some extra heat from mixing the buffers at the 
beginning and as they become more similar, the peak areas will decrease. The vCCI WT 
control was used instead of the vMIP-II control because it had a higher heat of dilution 
because it was more concentrated, and thus, it was a more appropriate control. Also, it 
can be seen to be a proper control by the fact that the later injections (already fully 
bound) average to about 0 after subtracting the control out (see Figure 3.6). This is what 
we would expect for a proper control. 
 The vCCI Y80A binding experiment data was processed by manually fitting the 
baseline and selecting 250 second integration regions for injections 1-8, 300 second 
integration regions for injections 9-14, and 150 second integration regions for injections 
15-20. At first, the vCCI Y80A control was subtracted out, but its average peak area was 
a little more than the peak areas of the last few injections of the binding experiment, so it 
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was not the best control. Therefore, the average peak area of the last 5 injections of the 
binding experiment (-7.53 µJ) was subtracted from the data as the area correction. This 
is accepted in literature and in data processing protocols of test experiments for ITC. 
 
 
 
Figure 3.7. ITC corrected heat rates resulting from approximately 170 µM vCCI Y80A 
titrated into 20 µM vMIP-II. As described in the legend above, red corresponds to the 
binding experiment, blue is the vCCI Y80A into buffer control, and black is the buffer into 
vMIP-II control. The top graph shows the 3 experiments stacked on top of each other 
and the bottom graph shows them all overlaid. 
42 
 
 
 
Figure 3.8. vCCI Y80A binding of vMIP-II modelled using the One Site Enthalpy Adjust 
model in NanoAnalyze, which is the same as the Independent model but also provides 
an additional adjusted enthalpy term for n=1, with nothing else changed. The binding 
experiment (red) shown above had its average area of injections 15 – 20 subtracted 
from itself. This is explained more in the text. The first data point was omitted from the fit, 
which is widely accepted and expected. 
 
The stoichiometric ratios (n) for both complexes were close to 1, as expected. 
Also, the KD for vCCI Y80A was higher than that for vCCI WT binding with vMIP-II, as we 
expected. Originally, I expected vCCI Y80A to have an even higher KD than we saw from 
these experiments because it was shown to abolish function in the White, et al paper.16 It 
is worth noting that the paper looked at how vCCI affected RANTES, not vMIP-II. I would 
expect RANTES to have an even higher KD than vMIP-II for binding vCCI Y80A. 
Nevertheless, in thinking about the White, et al. results in light of my data, the KD we 
obtained still makes sense with the loss of functionality they saw because of the 
concentrations they were using in their experiments. They incubated 5 nM RANTES with 
15 nM vCCI Y80A for two hours before their experiment. KD is the concentration of a 
ligand where it will be bound to half of its available binding partner. Given that we 
calculated the KD of vCCI Y80A with vMIP-II to be 30 nM (and it is expected to be even 
higher for RANTES), then at equilibrium, very little of RANTES would have been bound 
by vCCI Y80A. Thus, if they changed their experimental concentrations to be higher, 
they would likely see some of vCCI Y80A’s function, though it would be less potent than 
wild-type vCCI. Thus, our KD is congruent with their results. The clear next steps are to 
repeat these experiments at the same concentrations as well as do binding experiments 
with RANTES to see if it has a significantly worse KD with vCCI Y80A. While doing 
binding experiments with RANTES has been an issue due to aggregation in the past, the 
improved methods to reduce aggregation recently implemented should make it possible 
to get good data.  
ITC is not ideal for complexes with KD’s this small because the concentrations 
needed for the experiment are much higher than the KD, so all of the binding partner that 
is titrated in is immediately bound until all of the protein in the cell is fully bound, then 
smaller heat is released upon further addition of the binding partner because no 
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additional binding is occurring. This looks like a very quick transition between not fully 
bound and fully bound. You can tell from the data that it is tight binding and the data can 
be fit, but with the noise in the experiment, it makes it more difficult to feel confident that 
the KD’s are totally accurate. Repetition of the experiments and performing the 
experiments with the same concentration of vCCI WT and vCCI Y80A needs to be done 
to confirm the results seen in the singlet shown in this thesis. If the experiments were 
done near nM concentrations, one could also be confident, but there would not be 
enough signal above the noise to make sense of the data. For these reasons, 
fluorescence or SPR are good options for complexes with low KD’s. The ITC data we 
obtained was useful in giving us a close approximation of the KD’s and can be further 
bolstered by repeating the experiments but overall, fluorescence or SPR would be good 
techniques to use in the future. 
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Chapter 4 
 
Conclusions and Future Directions 
Overall, the experiments performed increased our knowledge about the vCCI 
Y80A mutant. Through CD, the melting temperature of vCCI Y80A was found to be 
6.1°C lower than that of WT. The CD spectra at the beginning and end of the 25°C to 
95°C temperature ramp were nearly identical. This suggests that the secondary 
structures at the beginning and end of the temperature ramp were very similar. Through 
NMR HSQCs, the changes in chemical shifts between unbound vCCI WT and vCCI 
Y80A were analyzed. The largest shifts were seen in residues in the early 50’s, early 
80’s, early to mid 90’s, and 145. Many of these residues have previously been 
determined to be important for vCCI binding.10,11,18 This suggests that these residues are 
in different chemical environments, which supports our hypothesis that residues which 
are part of the binding pocket are in different locations than in WT vCCI.  
The ITC results showed that both vCCI WT and vCCI Y80A are relatively tight 
binders, but vCCI Y80A has a larger KD than vCCI WT. It was originally surprising that 
the KD of vCCI Y80A with vMIP-II was found to be about 30 nM by ITC, but in looking 
back over the experimental set up by White, et al., it is congruent with their results.16 
Most of the RANTES in their pre-incubated mixture with vCCI Y80A would be free with a 
KD of 30 nM or greater (for wild type vCCI, RANTES has a 4x higher KD than vMIP-II) 
because they were using such low concentrations in their experiments. Thus, vCCI 
Y80A would not show much inhibitory effect. 
The two main areas of focus going forward on this project are binding studies 
and NMR relaxation studies. For the binding studies, ITC will be used to repeat the 
experiments already done and to do RANTES binding. SPR and fluorescence will also 
be explored as options to obtain more accurate KD values (because they are so low) and 
kinetic information. We predict that vCCI Y80A binding would have a slower on-rate, but 
a less- or non-affected off-rate. This is in contrast to what was seen for Y80R, which had 
an unaffected on-rate, but a faster off-rate.17 This makes sense because R is bulky and 
could hold the loop open, but the positive charge was repulsive to the lysine on the 
chemokine. 
NMR relaxation is a very promising way for us to test loop dynamics. vCCI Y80A 
will need to be assigned by 13C, 15N isotopic labeling of the protein. Then, NOE and 
CPMG experiments will be done to see if differences in relaxation of the loop region can 
be seen at nanosecond and micro- to millisecond time scales, respectively. Simulation 
data sees stable loop collapse for at least one microsecond. So, it will be great to test 
that experimentally via NMR. Also, we plan to obtain NMR HSQCs of labeled vCCI Y80A 
bound to non-labeled vMIP-II and labeled vMIP-II bound non-labeled vCCI Y80A. 
Additionally, more mutants will need to be made to further test hypotheses 
generated by MD results, such as changes to the N-terminus (length or charge) and 
double mutants of Y80A and N-terminal alterations. MD simulations done by Lauren 
Stark suggest that the N-terminus length or charge could be helping to keep the loop 
open and have a partial rescue effect on binding for the Y80A mutant. The double 
mutants will help us test this. We hypothesize that a double mutant of Y80A and an N-
terminal truncation or reduction of positive charge would have a higher KD than vCCI 
with a sole Y80A mutation. We also plan to also investigate other poxvirus strains of 
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vCCI. For instance, mousepox has a shorter loop and we are interested in seeing how 
that affects binding and with comparable mutations to the N-terminus and Y80A in 
rabbitpox vCCI (which we have been using). 
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